BMO Capital Markets restated their outperform rating on shares of Celgene Corp. (NASDAQ:CELG) in a research note issued to investors on Tuesday morning. BMO Capital Markets currently has a $141.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on CELG. RBC Capital Markets reaffirmed a buy rating on shares of Celgene Corp. in a report on Tuesday, July 26th. Piper Jaffray Cos. reaffirmed a buy rating on shares of Celgene Corp. in a report on Monday, September 12th. Jefferies Group reissued a buy rating and issued a $138.00 price target on shares of Celgene Corp. in a report on Tuesday, July 26th. Vetr lowered shares of Celgene Corp. from a strong-buy rating to a buy rating and set a $120.74 price target for the company. in a report on Thursday, June 2nd. Finally, JMP Securities reissued a buy rating and issued a $152.00 price target on shares of Celgene Corp. in a report on Thursday, June 23rd. Four research analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $138.10.

Shares of Celgene Corp. (NASDAQ:CELG) opened at 108.54 on Tuesday. The stock has a 50 day moving average of $110.62 and a 200 day moving average of $104.86. The company has a market cap of $84.13 billion, a price-to-earnings ratio of 45.87 and a beta of 1.31. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $128.39.

Celgene Corp. (NASDAQ:CELG) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.05. The firm earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. The business’s quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. Equities research analysts predict that Celgene Corp. will post $5.71 earnings per share for the current fiscal year.

In other Celgene Corp. news, Director Gilla Kaplan sold 9,710 shares of the stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total value of $1,033,532.40. Following the transaction, the director now directly owns 72,142 shares in the company, valued at $7,678,794.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the completion of the transaction, the insider now owns 1,022,201 shares in the company, valued at $112,442,110. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of CELG. Jolley Asset Management LLC increased its stake in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 450 shares during the last quarter. Smithfield Trust Co. increased its stake in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares during the last quarter. Kings Point Capital Management increased its stake in Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 22 shares during the last quarter. Integrated Investment Consultants LLC increased its stake in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 240 shares during the last quarter. Finally, Ropes Wealth Advisors LLC increased its stake in Celgene Corp. by 0.9% in the first quarter. Ropes Wealth Advisors LLC now owns 1,477 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 13 shares during the last quarter. 77.81% of the stock is owned by institutional investors and hedge funds.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.